Skip to main content

J3247: Permanent J-code for the IV formulation of COSENTYX®*

Effective July 1, 2024, for all sites of care

*If COSENTYX is administered on or after July 1, 2024, the permanent J-code replaces the miscellaneous J-code J3590.
It is the sole responsibility of the healthcare provider to select the proper codes and ensure the accuracy of all statements used in seeking coverage and reimbursement for an individual patient. Novartis cannot guarantee insurance coverage or reimbursement. 

Reference: CMS, HCPCS Quarterly Update, April 2024.

desktop-nr-axspa

Cosentyx address hallmarks of disease icon

Here with you to help address the hallmarks of disease that matter to patients with nr-axSpA 

Dr. Anne Winkler urgency of treating
Improvement in mean scores in nr-axSpA with 150 mg dose at Year 17
Improvement in Mean Scores for nr-axSpA with 150-mg Dose

In PREVENT, the above measures were prespecified exploratory end points in subgroups of biologic-naive patients at Year 1. No clinical or statistical conclusions can be drawn.8

Look deeper—reductions in SI joint inflammation in nr-axSpAe,f
A robust safety profile in
nr-axSpAf,m

Learn about a positive injection experience with COSENTYXo

*40% of biologic-naive patients achieved ASAS40 at 1 year on COSENTYX 150 mg no load (n=166) vs 20% on placebo (n=171) (NRI; P<0.05) (PREVENT primary end point).9 
Mean baseline morning stiffness score at Year 1: 7.2 (150 mg load group). Morning stiffness was measured by BASDAI questions 5 (mean duration) and 6 (severity), measured on a 0 to 10 numeric response scale.7,8 
Mean baseline fatigue score at Year 1: 21.9 (150 mg load group). Fatigue was measured by FACIT-Fatigue, a 13-item questionnaire that assesses self-reported fatigue and its impact on daily activities and function.7,8 
Mean baseline spinal pain score at Year 1: 73.7 (150 mg load group). Spinal pain was measured using a 100-mm VAS as a component of ASAS.7,8 
Mean baseline nocturnal back pain score at Year 1: 70.6 (150 mg load group). Nocturnal pain was measured using a 100-mm VAS as a component of ASAS.7,8

*Limitations apply. Up to a $16,000 annual limit. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice. Limitations may apply in MA and CA. For complete Terms and Conditions details, call 1-844-267-3689.

Definitions

AS, ankylosing spondylitis; ASAS, Assessment of SpondyloArthritis international Society criteria; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; FACIT, Functional Assessment of Chronic Illness Therapy; IL, interleukin; IV, intravenous; nr-axSpA, non-radiographic axial spondyloarthritis; NRI, nonresponder imputation; PsA, psoriatic arthritis; SC, subcutaneous; VAS, visual analog scale.

References

  1. Cosentyx. Prescribing information. Novartis Pharmaceuticals Corp.

  2. Remicade. Prescribing information. Janssen Biotech Inc. 

  3. Simponi Aria. Prescribing information. Janssen Biotech Inc.

  4. Orencia. Prescribing information. Bristol-Myers Squibb Co. 

  5. Taltz. Prescribing information. Eli Lilly & Co. 

  6. Siliq. Prescribing information. Bausch Health US LLC.

  7. Data on file. CAIN457H2315 Data Analysis Report. Novartis Pharmaceuticals Corp; April 2020.

  8. Data on file. CAIN457H2315 Clinical Study Report. Novartis Pharmaceuticals Corp; November 2019.

  9. Deodhar A, Blanco R, Dokoupilová E, et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study. Arthritis Rheumatol. 2021;73(1):110-120 and Supplementary Material. 

    a. Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2021;80(5):582-590.

    b. Data on file. CAIN457F2342 (FUTURE 5): 2-Year Interim Report. Novartis Pharmaceuticals Corp; May 2019.

    c. Data on file. CAIN457F2342 (FUTURE 5): 2-Year Interim Report PASI 90 and ACR Components data. Novartis Pharmaceuticals Corp; January 2020.

    d. Data on file. CAIN457F2342 (FUTURE 5): 2-Year Interim Report mNAPSI and PASI 100 data. Novartis Pharmaceuticals Corp; October 2019.

    e. Data on file. CAIN457H2315 Data Analysis Report. Novartis Pharmaceuticals Corp; April 2020.

    f. Data on file. CAIN457H2315 Clinical Study Report. Novartis Pharmaceuticals Corp; November 2019.

    g. Data on file. CAIN457F2310 Data Analysis Report. Novartis Pharmaceuticals Corp; June 2019.

    h. Data on file. CAIN457F2310 (MEASURE 2): Nocturnal Back Pain. Novartis Pharmaceuticals Corp; February 2021.

    i. Data on file. CAIN457F2342 (FUTURE 5): Interim Data Analysis Report FACIT-Fatigue data through Week 52. Novartis Pharmaceuticals Corp; April 2019.

    j. Poddubnyy DA, Rudwaleit M, Listing J, Braun J, Sieper J. Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis. 2010;69(7):1338-1341.

    k. Data on file. CAIN457F2342 Clinical Study Report Interim Analysis-Week 24. Novartis Pharmaceuticals Corp; November 2017.

    l. Data on file. CAIN457F2342 (FUTURE 5): 2-Year HAQ-DI biologic-naive data. Novartis Pharmaceuticals Corp; February 2021.

    m. Cosentyx. Prescribing information. Novartis Pharmaceuticals Corp.

    n. Data on file. Selected EAIRs MEASURE 2 Year 5. Novartis Pharmaceuticals Corp; January 2020.

    o. Nash P, Mease PJ, McInnes IB, et al; on behalf of the FUTURE 3 study group. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther. 2018;20(1):47.

    p. Data on file. LTD Cosentyx Prescriber and Patient Counts. Novartis Pharmaceuticals Corp; July 2021.

    q. Boonen A, Sieper J, van der Heijde D, et al. The burden of non-radiographic axial spondyloarthritis. Semin Arthritis Rheum. 2015;44(5):556-562.